yaozh.comzy.yaozh.com › instruct › sms20170707 › 1.pdf · p-gp cyp3a4, auc 1.5 1.6 cyp3a4...

3

Upload: others

Post on 29-Jun-2020

3 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

TRANSCRIPT

Page 1: yaozh.comzy.yaozh.com › instruct › sms20170707 › 1.pdf · P-gp CYP3A4, AUC 1.5 1.6 CYP3A4 CYP3A41k P-gp : CYP3A4 P-gp , CYP3A4 P-gp (5mg, (40mg, ) (325mg, (75mg, ( PT, APTT)

Page 2: yaozh.comzy.yaozh.com › instruct › sms20170707 › 1.pdf · P-gp CYP3A4, AUC 1.5 1.6 CYP3A4 CYP3A41k P-gp : CYP3A4 P-gp , CYP3A4 P-gp (5mg, (40mg, ) (325mg, (75mg, ( PT, APTT)

Page 3: yaozh.comzy.yaozh.com › instruct › sms20170707 › 1.pdf · P-gp CYP3A4, AUC 1.5 1.6 CYP3A4 CYP3A41k P-gp : CYP3A4 P-gp , CYP3A4 P-gp (5mg, (40mg, ) (325mg, (75mg, ( PT, APTT)

VEDLEGG I PREPARATOMTALE...samtidig bruk av CYP2D6- eller CYP3A4-hemmer vurderes på nytt. Samtidig administrering av CYP3A4- induktorer og Abilify Maintena skal unngås i mer enn

cyP3A4 inhibitor A TOXICITY · 2020. 7. 1. · Linagliptin Vildagliptin Saxagliptin Sitagliptin TOXICITY PARA cyP3A4 inhibitor A OF STATINS INHIBIT RELEASE OF INFLAMMATORY CYTOKINES

Evaluating A Potential CYP3A4 Selective Inhibitor With MD

C OVÁRIO INFLUÊNCIA DE POLIMORFISMOS NOS CYP3A4 E LIG4 ...€¦ · Cancro do Ovário: Influência de polimorfismos nos genes CYP3A4 e LIG4 na susceptibilidade e resposta farmacogenómica

HIGHLIGHTS OF PRESCRIBING INFORMATION ... · Strong CYP3A4 inhibitors or fluconazole 1,000 mg once daily ; Strong or moderate CYP3A4 inducers : 2,500 mg once daily

PENGARUH POLIMORFISME GEN CYP3A4 DAN DURASI … · 2019. 1. 12. · Tujuan penelitian ini adalah untuk mengetahui pengaruh polimorfisme gen CYP3A4 dan durasi pemakaian simvastatin

Inhibition of CYP2C19 and CYP3A4 by Omeprazole Metabolites ...dmd.aspetjournals.org/content/dmd/early/2013/04/25/... · DMD/2013/051722 2 Running Title: CYP2C19 and CYP3A4 Inhibition

Studies on Drug Interactions between CYP3A4 Inhibitors and

Ghid clinic de tratament substitutiv al dependenței de opiacee · CYP2C19, CYP3A4) sau în tubul digestiv (CYP3A4). Există o mare variabilitate individuală a conținutului în

FARMAKOVIGJILENCAomi.al/.../materialet-e-trajnimit-te-farmakovigjilences.docx · Web viewKonsiderohet si makrolidi me i sigurt per terapi sebashku me agjent qe bllokojne CYP3A4. CYP3A4

PRILOG I. - European Medicines Agency · CYP3A4/5 i P-glikoproteina) ili nakon 6 dana flukonazola 200 mg/dan (inhibitor CYP2C9, CYP2C19 i CYP3A4/5) u zdravih ispitanika, opaženo

Evaluation of Normalization Methods To Predict CYP3A4 ...dmd.aspetjournals.org/content/dmd/44/1/50.full.pdf · Evaluation of Normalization Methods To Predict CYP3A4 Induction in

INVESTIGATION OF THE IN CYTOCHROME P450 CYP3A4 ... · CYPIBI, CYP2A6, CYPZA7, CYP2C9, CYPtCI8, CYP2C19, CYP2D6, CYP2E1, CYP3A4 and CYP3A5 (Table 1). Important allelic members of the

ANEXA I REZUMATUL CARACTERISTICILOR … · Administrare concomitentă cu inductori puternici ai CYP3A4/5 precum rifampicină, ... CYP3A4 şi/sau ai CYP3A5 poate reduce concentraţiileplasmatice

ANEXA I REZUMATUL CARACTERISTICILOR PRODUSULUI · pasaj hepatic, mediată de enzima CYP3A4. Se recomandă precauţie la administrarea concomitentă cu inhibitori puternici ai CYP3A4

Characterization of the CYP3A4 Enzyme Inhibition Potential

HIGHLIGHTS OF PRESCRIBING INFORMATION Macular Edema: …€¦ · 7.4 Vaccination 7.5 CYP2C9 and CYP3A4 Inhibitors 7.6 CYP2C9 and CYP3A4 Inducers 8 USE IN SPECIFIC POPULATIONS 8.1

Strong inducers of CYP3A4/5 and in · Strong inducers of CYP3A4/5 and in ... injection, for intravenous infusion only ... a washout period of approximately 1

Selection of Alternative CYP3A4 Probe Substrates for ...dmd.aspetjournals.org/content/dmd/early/2010/03/04/dmd.110.0320… · develop a strategy for selecting alternate CYP3A4 probe

USER MANUAL (GB) P 01 GP CA MANUEL D’UTILISATION (FR) P …

Review Article Interactions between CYP3A4 and Dietary

Pharmacological P-gp identification Since P-gp mediated drug efflux is a major hurdle in CNS drug discovery, it is important to identify P-gp substrates

CYP3A4 · 2020-07-15 · 폐경후질출혈 2019.05.07 cyp3a4 억제제: 트리암시놀론은 cyp3a4 기질이다. 케 토코나졸은 특정 코르티코스테로이드제의 대사를

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS · Ranolazine is a moderate to potent inhibitor of P-gp and a mild inhibitor of CYP3A4, and may increase plasma concentrations of P-gp or

1er P. GP-histo Modificada

ANEXO I FICHA TÉCNICA O RESUMEN DE LAS …...Medicamentos quimioterapéuticos que son sustratos de CYP3A4 Netupitant es un inhibidor moderado de CYP3A4 y puede aumentar la exposición

Utjecaj polimorfizama CYP3A4/5 i CYP2D6 na serumske

ALLEGATO I RIASSUNTO DELLE CARATTERISTICHE DEL …€¦ · 6 Inibitori CYP3A4 L'uso concomitante di inibitori potenti del CYP3A4 deve essere evitato. Se gli inibitori potenti del

Flavonoid-Drug Interactions: Effects of Flavonoids …Flavonoid-P-gp Interactions Mechanisms: ¾Biochanin A is not a substrate ¾Flavonoids affect P-gp ATPase activity or the P-gp

DO ZERO AOS 10K - s3-eu-west-1.amazonaws.com · AULAS G¼¯¹¯ÀÆp; ¯© ¼| p£; | pª ¯;Gp¼| ¼ pÀ ¼ À p;Jq¹ ¯ ; À; ÀÆ¼pÆ pÀ;Gp¼p | £ ¼p¼;NÊpÀ;J À;

PENGARUH POLIMORFISME GEN CYP3A4 DAN DURASI …erepository.uwks.ac.id/2980/1/Abstrak (upload).pdfsendiri di metabolisme oleh enzim CYP3A4, enzim ini aktifitasnya diatur oleh gen CYP3A4

€¦ · 50 1% 55-370b IJ7jY5P CYP3A4 CYP3A4 CtlBD 1) 1) (D 95370b cnB CYP3A4 ct1BD æn-so 22)

Programm · von CYP3A4/5, ein leichter Induktor von CYP2B6 und ein leichter Inhibitor des P-Glycoproteins (P-gp), des organischen Kationentransporters 2 (OCT2) und der Uridin-Diphosphat-Glucuronosyltransferase

Jordi Fontcuberta Unitat d’Hemostasia i Trombosi Servei .... Jordi...Inhibidor bomba protones Inhibidor potente de CYP3A4 y glicoproteina P Inhibidor potente de CYP3A4 y glicoproteina

Mechanism-based Inhibition of CYP1A1 and CYP3A4 by the